Abstract
L-homoarginine (L-hArg) is an endogenous non-proteinogenic amino acid. Low L-hArg concentrations are associated with increased all-cause mortality, fatal strokes, and worse outcome after stroke. On the other hand, oral supplementation with L-hArg in mice improved neurological deficits and preserved cardiac function in experimental models of stroke and heart failure, respectively. Recently, oral supplementation with 125 mg daily L-hArg capsules in healthy volunteers demonstrated increased L-hArg plasma levels. Therefore, oral L-hArg supplementation could represent a potential treatment for patients with cerebrovascular disease. In addition to vascular physiology, animal studies have suggested that L-hArg might play a role in synapse function, neurotransmitter metabolism and cognitive training. However the direct influence of L-hArg on cognitive function has not been studied so far. In this study, cognitive performance in healthy humans was analyzed concerning memory, learning, and attention following supplementation with placebo or L-hArg for 4 weeks. Our results did not reveal any effects on cognition, neither impairment nor improvement, upon L-hArg supplementation. Therefore, potential L-hArg treatment is not expected to cause any acute neurocognitive or behavioral side effects.
| Item Type: | Journal article |
|---|---|
| Faculties: | Medicine |
| Subjects: | 600 Technology > 610 Medicine and health |
| ISSN: | 0967-5868 |
| Language: | English |
| Item ID: | 65089 |
| Date Deposited: | 19. Jul 2019, 12:16 |
| Last Modified: | 04. Nov 2020, 13:45 |
Actions (login required)
- View Item
